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Abstract 
  
Background Intravenous (IV) drug delivery is commonly used for its rapid administration and 
immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and 
efficacy but little is known about what patients prefer.  
Methods A systematic review was conducted by searching 7 electronic databases for articles 
published up to February 2014. Included studies were randomised controlled trials (RCTs) or cross 
over designs investigating patient preference for SC versus IV administration. The risk of bias in the 
RCTs was determined using Cochrane Collaborations tool. Reviewers independently extracted data 
and assessed the risk of bias. Any discrepancies were resolved by consensus.  
Results The search identified 115 publications, but few (6/115) met the inclusion criteria. Patient 
populations and drugs investigated were diverse. 4/6 studies demonstrated a clear patient preference 
for SC administration. Main factors associated with SC preference were time saving and the ability to 
have treatment at home. Only 3 studies used study-specific instruments to measure preference.  
Conclusions Results suggest that SC is the patients’ preferred route of drug delivery. Patient 
preference has clearly been neglected but it is important in medical decision making when choosing 
treatment methods as it has implications for adherence and quality of life. If the safety and efficacy of 
both administration routes are equivalent then the most important factor is patient preference. Future 
drug efficacy and safety studies should include patient preference and use adequate measures.   
 
 
Key Points: 
 Results suggest that the SC route is the patients preferred method of drug delivery 
 Patient preference needs to be addressed in future RCTs. This is important when selecting 
methods of treatment as it has implications for adherence and quality of life  
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Introduction 
Many drugs can be given in a variety of different ways, oral, parenteral, intravenous and 
subcutaneous. All have their potential advantages and disadvantages in terms of patients’ 
convenience, pain, discomfort and impact on emotional and social well-being. If drugs have similar 
efficacy then patient preference for route of administration could be important and should support 
medical decision making. The various drug modalities, dosages and frequencies offer a wide option of 
choices to suit patients’ needs and preferences. Consideration of such factors may help address the 
problem of treatment adherence especially in chronic medical conditions. Improvements in modern 
treatments have turned some diseases into chronic conditions (such as diabetes and cancer) so 
determining individual acceptability and choice of type of drug administration could enhance 
adherence to therapeutic regimens.         
 The intravenous (IV) and subcutaneous (SC) routes of administration have both benefits and 
drawbacks. IV delivery is advantageous as it allows an immediate effect of the drug to take place, the 
rate of distribution can be controlled, it assists those patients who cannot tolerate a drug orally or have 
swallowing difficulties, large doses can be infused expeditiously, and it permits continuous 
medication to be delivered [1]. Advantages of the SC route include the possibility of self-
administration, greater mobility for patients, it provides an alternative for patients with poor venous 
access and can be administered at home, away from the hospital setting [2]. Cost is another element to 
take into account, and several studies have shown the cost effectiveness of SC delivery over the IV 
drug route [3-6]. In addition, out of pocket costs for patients and their families having to take time off 
work and travel to hospital for IV treatment could be underestimated.     
 There have been trials comparing IV and SC drug administration with most reporting on drug 
efficacy and safety [7-16]. In the study by Moreau et al (2011) [11], patients with relapsed multiple 
myeloma (MM) were randomised to receive bortezomib either by SC administration or IV infusion. 
Results revealed that the efficacy of SC bortezomib was non-inferior to IV administration. Adverse 
events were reported in 57% of patients in the SC group and 70% in the IV group, showing that SC 
has an improved safety profile. Because of these results the SC route of bortezomib was authorised for 
use within Europe [17]. Although the drug was approved, and fewer adverse events might lead to 
reasonable assumptions that patients would prefer SC delivery, these were not reported.   
 A recent study [16] has demonstrated that the pharmacokinetic profile of SC rituximab in 
patients with previously untreated follicular lymphoma was non-inferior to IV rituximab and was not 
associated with new safety concerns. IV infusions lasted 1.5 to 6 hours, whilst the median injection 
time for SC rituximab was 6 minutes, showing that SC delivery would improve convenience for the 
patient whilst decreasing the burden on healthcare costs. This study is currently investigating the 
views of the health care professionals regarding their preferred administration route, however it will 
not report on patient preference.         
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 Some drugs are available in both IV and SC formulations permitting patients receiving long 
term treatment who can no longer tolerate IV therapy, to be given the drug subcutaneously, when for 
example repeated cannulation may have damaged peripheral veins. This is demonstrated in a study by 
Keystone et al (2012) [14]. Patients with rheumatoid arthritis who received at least four years of IV 
abatacept continued via the SC method. Safety, efficacy and immunogenicity was investigated and 
results showed that switching from IV to SC administration was well tolerated, had no increased 
safety concerns, no increased risk of immunogenicity and efficacy was maintained. These features 
paired with the fact that fewer than 10% of patients discontinued SC treatment suggests that patients 
may well prefer SC administration although the study did not investigate this formally.  
 There are in fact few studies where patients’ preferences or acceptance for IV and SC drug 
administration are primary outcomes [18-24]. A good example is the report by Barbee et al (2013) 
[19] in which patients with MM who received at least one dose each of IV and SC bortezomib were 
asked via a questionnaire about their preference for route of drug delivery; 68% preferred SC whilst 
25% favoured IV. However as with many other studies, this was not a randomised controlled trial 
(RCT). Such designs may affect outcomes because of the lack of random allocation to intervention 
groups that might have introduced bias [25].        
 A better understanding of patient preference is fundamental in assisting medical decision-
making, particularly in patients with chronic health conditions where patients may be receiving 
treatment for long periods of time. In this systematic literature review, we investigated patient 
preferences for IV or SC drug administration which had been examined in RCTs or crossover designs. 
Methods  
Search strategy 
A systematic, electronic search of AMED, CINAHL, MEDLINE, PsycINFO, PUBMED, SCOPUS 
and Science Direct was performed for articles published up until February 2014. A combined search 
was used including the terms ‘preference’, ‘intravenous vs. subcutaneous’ OR ‘intravenous versus 
subcutaneous’ in the various databases. No restrictions regarding the time period or the type of study 
were applied during the initial search. A hand search was conducted on the relevant papers retrieved, 
to examine additional related studies.   
Selection Criteria  
All duplicates were excluded from the initial computerised search. Only publications of studies that 
met the following criteria were included: (1) comparison of SC with IV drug administration, (2) 
investigation of patients’ preferences for SC and IV drug administration, (3) either a RCT or cross-
over study design, (4) original full reports (i.e. conference abstracts or posters, reviews, meta-
analyses, and commentaries were excluded) and (5) adults over 18yrs. In the first selection stage 
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titles, abstracts and information on the studies were screened to assess whether they were original full 
reports. In the second stage, abstracts and/or full copies of the articles were reviewed for final 
selection by two reviewers (KS and HH), followed by the hand search.  
Methodological quality assessment 
The methodological quality of each article was assessed using the Cochrane Collaboration’s tool for 
assessing risk of bias, which rates the quality of RCTs [26]. The original version of the tool consists 
of seven items that are used to assess the risk of bias in the RCTs. However for this systematic review 
the item ‘blinding of participants and personnel’ was removed due to the nature of the intervention (it 
is not feasible to mask for treatment allocation). This resulted in a six-item scoring system using 
random sequence generation, allocation concealment, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other bias. A judgement of risk of bias was assigned to each 
scoring item (1=low bias, 0=high bias or unclear bias,) and a total risk of bias score was calculated. 
Each trial was then assigned a quality rating based on the number of low risk judgements ranging 
from good quality (total score 5-6), fair quality (3-4) to poor quality (0-2). Two reviewers (KS and 
HH) independently assessed the methodological quality of the included studies. Any differences in 
rating and/or discrepancies were resolved following discussion. 
Results 
Search Results  
The search produced 151 hits (Figure 1) from 1974 to February 2014. Duplicates were excluded, 
leaving 115 potentially relevant studies. The titles, abstracts and information of these citations were 
screened for relevance to the review topic, leaving 34 studies to be assessed further. The abstracts 
and/or full texts of the 34 studies were retrieved, evaluated in detail and filtered according to the 
eligibility criteria. After this stage five studies were left for inclusion in the review [27-31]. A hand 
search of the references of relevant citations resulted in an additional study being included in the final 
review [32]. In total, 6 studies met the selection criteria and details are summarised in Table 1. 
 Four of the RCTs used a crossover design. A total of 410 participants were evaluated across 
the six studies. The sample sizes ranged from 9-248 participants at baseline. The age range of 
participants (taken from five studies that adequately reported the age range) was 18-85 years. The 
samples across the six studies predominantly focused on females (83% female, 17% male). The study 
population were diverse. Studies included participants with cancer, Crohn’s disease (CD), primary 
antibody deficiencies, multifocal motor neuropathy (MMN), primary invasive breast adenocarcinoma, 
deep vein thrombosis (DVT) and patients scheduled for elective abdominal or extremity surgery.  
Study quality 
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Three of the studies were of good methodological design with low risk of bias (see Table 1). The 
remaining three studies were of fair methodological quality. In the studies of a fair methodological 
quality, possible areas of bias were reported in ‘random sequence generation’ and ‘allocation 
concealment’. In general the studies seemed sound however the possibility of bias was raised due to 
under-reporting, particularly in earlier publications.  All studies showed a low risk of bias on the 
‘incomplete outcome data’.  
Patient preferences 
The majority (4/6) of the studies concluded that patients had demonstrated a preference for SC drug 
administration [27-30] proportions ranged from 44%-91%. Only one study reported that patients 
preferred IV drug delivery [32] and another found no difference in patient preference for either 
method [31].           
 Assche et al (2012) [28] investigated elective switching between anti-tumour necrosis factor 
agents in patients with CD. The 73 patients either continued receiving IV infliximab (IFX), or 
switched to SC adalimumab (ADA) administered every other week. Patient preference was 
investigated in the ADA arm with a study-specific questionnaire. SC ADA was preferred by patients 
at the majority of time points (6/7) throughout the trial but reasons for preference were not reported.
 The study by Harbo et al (2009) [29] was conducted on patients with MMN. Patients were 
randomised to either receive SC or IV immunoglobulin (Ig) of equal doses. The first therapy was 
given for a period of 18-56 days. Patients then crossed over to receive the alternative treatment. IV 
treatment was given in the hospital. During a hospital stay a nurse taught patients how to self-
administer SC Ig, allowing treatment to be administered at home. Patients gave a detailed description 
of their preference (method unknown). 44% (4/9) of patients had a predilection towards SC Ig, 22% 
(2/9) favoured IV administration and 33% (3/9) gave no preference.  Reasons given by patients for SC 
Ig preference were that treatment could be given at home and it allowed them to avoid difficulties 
with IV access. However, patients reported that the increased number in treatment days was a 
disadvantage for SC Ig.           
 Pivot et al (2013) [30] investigated the preferences of women with HER2-positive breast 
cancer for SC or IV trastuzumab. Patients were randomised to receive either four cycles of SC or IV 
trastuzumab and then crossed over to receive the alternative method of treatment. Two study-specific 
interviews gathered patient choices and reasons for preferred treatment; one was conducted at 
baseline, the other after the cross over period. 96% (112/117) patients who received SC trastuzumab 
first, favoured the SC route of administration whereas 4% (5/117) chose the IV route. In patients who 
received the IV route first, 87% (104/119) preferred SC, 9% (11/119) favoured IV delivery and 2% 
(4/119) had no preference. Overall 92% (216/236) of patients preferred SC and 7% (16/236) IV 
trastuzumab, 2% (4/236) had no preference. In 74% (159/216) of patients, the preference for SC was 
‘very strong’, ‘fairly strong’ in 21% (45/216) and ‘not very strong’ in 6% (12/216). Preference for IV 
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route was ‘very strong’ in 50% (8/16) of patients, ‘fairly strong’ in 19% (3/16) and ‘not very strong’ 
in 31% (5/16). Reasons for choosing SC were primarily time saving in 90% (195/216) of patients, less 
pain/discomfort in 41% (88/216), patient convenience in 16% (35/216), easier administration in 15% 
(33/216), problems with IV administration in 12% (25/216) and less stress and anxiety in 7% 
(15/216). One of the main reasons for the 16 patients preferring the IV route were that 69% (11/16) 
patients had fewer reactions (less pain, bruising irritation etc.) to that method.   
 Robinson’s et al study (1993) [27] focused on patients with DVT. Patients were randomised 
to receive calcium heparin SC or sodium heparin given IV. Patients then crossed over to receive the 
alternative treatment. At the end of the study patients were questioned on their overall partiality for 
form of treatment (method unknown). 79% (15/19) of patients favoured the SC route. 11% (2/19) 
chose the IV route and 11% (2/19) gave no preference. Patients reported significantly less discomfort 
felt at the SC injection site (p<0.001). Patients also perceived that their mobility was better during the 
last days of treatment when they were receiving SC heparin (p<0.005).     
 In contrast Chapel’s et al (2000) [32] study on patients with primary antibody deficiencies 
found that patients preferred IV method of drug administration. Patients received either SC or IV Ig 
therapy for one year and then received the alternative treatment for an additional year. At the end of 
the study patients were asked which method they preferred (methods not reported). Results showed 
that 62% (16/26) patients favoured IV application compared with 38% (10/26) patients who preferred 
the SC route. Four patients had no preference. Reasons for preference were not reported.   
 The study by Urquhart et al (1988) [31] assessed patient controlled analgesia (PCA) in 
patients undergoing elective abdominal or extremity surgery. Patients were randomised to receive 
either SC or IV PCA. When patients reported pain, hydromorphone was administered until they no 
longer experienced any discomfort. A PCA infuser was then attached to the patient, allowing patients 
to self-administer hydromorphone either IV or SC for the duration of their stay in the hospital. After 
completion of PCA therapy patients were asked about their overall satisfaction with the technique via 
a study-specific questionnaire. 80% (12/15) patients in the SC group rated their pain control as 
excellent, as did 67% (10/15) patients in the IV group. However there were no differences in the 
patients’ ratings of overall satisfaction in their analgesic therapy between both treatment groups.  
Quality of life (QoL) 
Two studies also reported on patients’ QoL in addition to preference. In the study by Harbo et al 2009 
[29], patients completed the generic SF-36 questionnaire [33]. The hypothesis was that QoL would 
improve in patients with MMN following SC delivery of Ig, as this could be given at home. Although 
SC administration was the route that was preferred by most of the patients in the study, no significant 
differences in the QoL scores were found.      
 Assche et al 2012 [28] used the disease-specific IBD questionnaire to measure QoL [34].  
This enquired about general preference, the benefit from therapy, mode of administration, impact on 
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activities of daily life, burden of adverse events and financial implications. Patients had a predilection 
for SC over IV on all aspects of QoL apart from the financial impact of treatment.  
Efficacy and safety 
Although the focus of this review is on patient preferences, the primary outcome in 4/6 studies [27, 
29, 31, 32] was to evaluate the the non-inferiority of SC to IV drug delivery, and all demonstrated 
comparable efficacy and safety profiles of the two methods of drug administration. The two studies 
[28, 30] that included patient preference in the primary study outcomes showed more diverse results 
regarding efficacy and safety. Pivot et al (2013) [30] concluded that SC trastuzumab is a valid 
treatment alternative because it has a similar safety profile as well as a pharmacokinetic profile and 
efficacy that is non-inferior to IV administration. In contrast, Assche et al (2013) [28] reported 
treatment termination because of a loss of tolerance in 10/36 patients receiving SC ADA compared to 
only 1 patient in the IV drug administration arm. A loss of efficacy was shown in 4/36 patients 
receiving SC ADA, however despite this patients still reported a preference for SC administration.  
Discussion 
 
The present review evaluated patients’ preferences within RCTs for either SC or IV drug 
administration. An extensive literature search revealed six RCTs [27-32]. Despite the heterogeneity of 
the studies, overall findings demonstrate clear patient preference ranging from 44% [29] to 91% [30] 
for the SC route. Factors associated with SC preference were that patients were able to have the 
treatment at home [29], saved time (e.g. travel time to the hospital) [29], avoided problems with IV 
administration or vein access [29, 30], and reduced discomfort [27].  
The studies included in this review not only showed diversity regarding patient population 
and the drugs investigated, but also in the period of time that the drugs were administrated. Treatment 
time ranged from two days in a PCA trial [31] to 2 years in a trial examining Ig replacement therapy 
in patients with primary antibody deficiencies [32]. This is important to take into account as patient 
preference for administration route may differ according to the length of time patients spend receiving 
the drug. For example, patients who require long-term drug treatment may experience damage to their 
veins, which no longer allows them to tolerate IV delivery. These patients may welcome SC 
administration, whereas those who are given drugs for a shorter duration or in a one-off-treatment 
may not be affected and therefore show little or no preference for mode of drug delivery. Our review 
confirmed that an increase in the length of required treatment was associated with preference for SC 
administration [28-30].          
 The outcome measures addressing patient preference varied between studies. Half of the 
studies lacked a description of study measures, resulting in a possible bias or problems regarding the 
validity of the results [27, 29, 32]. The three remaining studies used study-specific instruments either 
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questionnaires or field tested-interviews [28, 30, 31].  However, the fact that all measures were study-
specific highlights that patient preference is often overlooked in most drug administration trials as 
there are no validated instruments available. 
A strength of the current review is that only RCTs were included. Although there are other 
good quality studies that examine patients’ preferences [18-24], none are RCTs.    For example, one 
study measured preferences of IBD patients for two anti-TNF agents in terms of their mode of 
administration by using hypothetical scenarios [18]. However, until patients actually have the drugs 
administered and experience the different modes of delivery, the route they favour may differ.  
Our review has few limitations. One of these is the appraisal system we used [26]. This 
particular method focused on whether or not the study had properly been set up as an RCT to 
eliminate bias, rather than an in depth appraisal that may have been achieved by using another 
process. In addition, as blinding for treatment allocation was not possible in most studies - only one 
study was single-blinded [29], part of this tool could not be used.  
As far as we are aware this is the first review focusing on patients’ preferences for either IV 
or SC administration. One other review compared different aspects of SC and IV routes (including 
health related QoL, treatment satisfaction and convenience) but only included studies in patients with 
primary or secondary antibody deficiencies [35]. 
A partiality by patients for administration route is an important issue that needs more consideration 
especially as time is a very precious commodity for patients with life-threatening and/or chronic 
disease. The extra survival time achieved through efficacious drugs needs to be balanced against the 
efforts and burdens required to have the treatment administered. Both the lack of literature and the 
fact that only one study assessed patient preference as the primary outcome measure [30] demonstrate 
how this area is neglected. This evidence establishes that patients are not given the chance to decide 
which medical treatment is most beneficial to them. Patient preference is one of the most significant 
factors in treatment-related decision making and could possibly affect patient’s QoL and treatment 
compliance. 
Addressing patient preferences in future research is vital in regards to medical decision 
making. Future studies should include an RCT or crossover design and incorporate health-related 
QoL. There is also scope for some standardisation in the methodology employed to measure 
preferences as this would increase the validity within the research. If the safety and efficacy of the 
two methods is proven to be non-inferior to one another, patients should have a choice in what route 
they receive, based on what is beneficial to them. This is particularly the case for individuals who 
undergo long-term treatment for chronic diseases.   
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Table 1. Studies included in the final review  
Author, year & 
country 
Aims of study Sample Procedure Outcomes Results Appraisal/quality 
assessment  
 
Assche et al. 2012, 
Belgium single-
centre [28] 
 
To evaluate 
prospectively 
the impact of 
elective 
switching of 
patients with 
CD with IV 
IFX to SC 
ADA and to 
assess patient 
preference 
 
N=73. Median 
age 38 in ADA 
group and 37 in 
IFX group. Age 
range 27-47 
years.  
 
 
Patients 
received 
scheduled 
IFX 
maintenance 
for ≥ 6 
months before 
study 
participation. 
They were 
then 
randomised to 
either 
continue IV 
IFX (n=37) or 
switch to SC 
ADA (n=36) 
for 56 weeks 
 
Diary-based 
CDAI 
assessed 
disease 
activity. IBDQ 
measured 
QOL. Study-
specific 
questionnaire 
assessed 
general 
preference at 
different time 
points. Patient 
preference 
only assessed 
in SC ADA 
patients 
 
 
Significantly 
more patients 
preferred SC 
over IV 
(p=0.8 at 56 
weeks/end of 
study.) Clear 
preference (% 
not reported) 
for SC 
administered  
therapy for 
most items on 
study-specific 
questionnaire 
except 
financial 
impact of 
treatment  
 
 
Good quality 
5/6 low risk of 
bias 
 
Chapel et al. 2000, 
, International, 
multi-centre [32]  
To compare 
the efficacy of 
IV versus SC 
Ig replacement 
N=30. Mean age 
44 years. 20 
female, 10 male.   
Crossover, 
Cross-
overdesign. 
Patients 
Number, 
length and 
severity of 
infections was 
22 completed 
study (2 years 
of treatment); 
8 withdrew, 4 
Fair quality 
3/6 low risk of 
bias 
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therapy to 
prevent 
infections in 
patients with 
primary 
ADSs, and to 
assess patient 
preference for 
administration 
route  
randomised to 
receive SC or 
IV therapy for 
1 year and 
then switched 
to alternative 
treatment for 
1 year 
measured 
during 
treatment 
periods.  Days 
lost from 
school/ work 
due to 
infections 
recorded. 
Patient 
preference 
gathered at 
completion of 
study; 
methods 
unknown 
completed 
one phase. 
16preferred 
IV and 10 
preferred SC; 
4 had no 
preference   
 
Harbo et al. 2009, 
Denmark. multi-
centre [29] 
 
To investigate 
in patients 
with MMN, 
whether self-
infusions of 
SC Ig are as 
effective, 
feasible and 
safe as an IV 
infusion, and 
 
N=9. Mean age 
49 years. 5 
female, 4 male.  
All patients had  
IV Ig 
maintenance 
therapy prior to 
study inclusion    
 
Cross-over 
design. 
Patients 
randomised to 
receive SC Ig 
or IV Ig for 
18-56 days, 
followed by 
either IV or 
SC 
 
SF-36 
questionnaire 
assessed 
HRQOL. 
Patients 
described their 
preference for 
therapy; 
methods 
unknown.  
 
45% (4/9) 
preferred SC 
due to no end 
of dose 
weakening, 
treatment at 
home, 
avoidance 
difficulties IV 
access. 22% 
 
Good quality 
6/6 low risk of 
bias 
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whether SC 
self-infusions 
at home are 
associated 
with better 
QOL in 
comparison to 
IV 
administration. 
respectively   (2/9) 
preferred IV 
because of 
avoidance of 
treatments 
several times 
per week. 
33% (3/9) had 
no preference. 
No significant 
differences in 
QOL scores 
during SC and 
IV 
administration 
period 
 
Pivot et al. 
2013,International, 
multi-centre [30] 
 
To assess 
patient 
preference for 
SC or IV 
trastuzumab in 
the adjuvant 
breast cancer 
setting  
 
N=248 women 
with HER2-
positive primary 
invasive breast 
adenocarcinoma. 
Median age 53 
years.  Patients 
were either 
trastuzumab 
naïve or had 
 
Cross-over 
design. 
Patients were 
randomised to 
receive 4 
cycles of SC 
or IV 
trastuzumab, 
and then 
crossed over 
 
Two study 
specific 
telephone 
interviews 
assessed 
preferences 
and strength of 
preferences.  
 
236 patients 
were included 
in intention-
to-treat 
population. 
91% 
(216/236) 
patients 
preferred SC 
(P<0.0001). 
 
Good quality 
6/6 low risk of 
bias 
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already received 
IV trastuzumab 
as part of 
treatment 
to receive the 
other method 
of 
trastuzumab 
administration 
for 4 cycles.  
7% (16/236) 
preferred IV 
and 2% 
(4/236) had 
no preference. 
Preference of 
SC was very 
strong in 67% 
(159/236) 
 
Robinson et al. 
1993, UK, single-
centre [27] 
To assess and 
compare 
patient 
acceptability 
and 
preferences for 
SC versus IV 
heparin in the 
treatment of 
DVT 
N=20. Mean age 
55 years. 7 male, 
13 female.  
Cross-
overdesign. 
Patients 
received 
either IV or 
SC heparin 
for 3 days, 
and then 
crossed over 
to receive the 
other method 
of heparin 
administration 
for 3 days.  
VAS assessed 
acceptability 
of 
administration 
methods for 
discomfort in 
affected leg, 
pain at 
injection site, 
and mobility. 
Patients’ 
preference for 
method of 
administration 
was gathered 
at completion 
of study; 
78% (15/19) 
preferred SC 
(P<0.001). 
11% (2/19) 
preferred IV 
and 11% 
(2/19) gave 
no preference. 
Less 
discomfort at 
injection site 
with SC 
administration  
(p<.001) 
 
 
 
Fair quality 
3/6 low risk of 
bias 
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ADA Adalimumab, ADS Antibody Deficiency Syndrome, CD Crohn’s Disease, CDAI Crohn’s 
Disease Activity Index, DVT Deep Vein Thrombosis, HRQOL Health Related Quality of Life, HER2 
Human Epidermal Factor Receptor Type 2, Ig Immunoglobulin, IBDQ Inflammatory Bowel Disease 
Questionnaire, IFX Infliximab,  IV Intravenous, MMN Multifocal Motor Neuropathy, PCA Patient 
Controlled Analgesia, QOL Quality of Life, RCT Randomised Controlled Trial, SF-36 Short Form 36 
Item Questionnaire, SC Subcutaneous, VAS Visual Analogue Scale  
 
methods 
unknown.  
 
  
Urquhart et al. 
1988, USA single-
centre [31]  
To compare 
the efficacy of 
SC PCA to IV 
PCA in 
patients 
scheduled for 
elective 
abdominal or 
extremity 
surgery 
N=30. Mean age 
52 years in IV 
group, 44 years 
in SC group. 12 
male, 18 female.  
Patients 
received 
either IV 
(n=15) or SC 
PCA (n=15).  
5-point scale 
assessed 
postoperative 
analgesia at 4-
hr intervals. 
Study specific 
questionnaire 
assessed self-
reported 
incidence of 
side effects 
and overall 
satisfaction 
with route of 
administration.    
No difference 
between 
groups in self-
reported 
incidence of 
side effects or 
satisfaction 
with route of 
administration 
Fair quality  
3/6 low risk of 
bias 
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Search Terms: 
Preference AND Intravenous vs Subcutaneous 
OR Intravenous versus Subcutaneous 
 
 
Initial electronic database search 
(n=151)  
    
   
  
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Search Results 
 
AMED CINAHL MEDLINE PsycINFO PUBMED SCOPUS SCIENCE 
DIRECT 
2 
25 
1
7 
5 
16 
2
7 
59 
Duplicates Excluded (n=36)  
 
   ) 
Potential relevant titles and 
abstracts were screened 
(n=115) 
Excluded because of irrelevance 
(n=81)  
Abstracts/full text retrieved for 
more detailed evaluation 
(n=34) 
Excluded (n=28):                                                     
Not investigating IV vs SC (n=3); 
Not involving preference (n=14); 
Not RCT or cross over studies 
(n=7); Reviews (n=2); 
Commentaries (n=2); Involving 
children (n=1)                
 
                 
Appropriate RCT studies 
identified to be included in the 
review (n=6) 
Additional studies from hand 
search. (n=1) 
Databases 
 
